We use our in-depth knowledge and expertise in constantly generating nanobodies against numerous targets within a wide range of projects.
We cover the whole process for nanobody generation starting from antigen production for immunization of alpacas, establishing VHH gene libraries, and the screening and validation of nanobodies.
In addition to newly immunized VHH gene libraries we widely use our highly diverse (3 x 108) non-immunized naive VHH library for binder selection.
Initially selected nanobodies are routinely characterized regarding their domain/epitope binding, affinities and extra- and intracellular functionality.
Our expertise in nanobody generation is part of many own research projects as well as collaboration projects with partners from academia and the pharmaceutical industry.
We are permanently looking for novel interesting nanobody targets and are open for any kind of collaboration.